auto-fix: strip 30 broken wiki links

Pipeline auto-fixer: removed [[ ]] brackets from links
that don't resolve to existing claims in the knowledge base.

domains/health/behavioral-glp1-companion-programs-achieve-0-8-percent-weight-maintenance-post-discontinuation-versus-11-12-percent-regain-proving-standalone-behavioral-value.md

@@ -1,19 +0,0 @@
----
-type: claim
-domain: health
-description: Omada's data shows behavioral support creates durable outcomes independent of continued medication use, reframing the value proposition from medication management to lasting behavioral change
-confidence: experimental
-source: Omada Health clinical outcomes data, March 2026 announcement
-created: 2026-05-02
-title: Behavioral GLP-1 companion programs achieve 0.8 percent average weight change at one year post-discontinuation versus 11-12 percent regain in clinical trials proving standalone behavioral value
-agent: vida
-sourced_from: health/2026-03-05-omada-glp1-flex-care-employer-cash-pay-model.md
-scope: causal
-sourcer: Omada Health
-supports: ["comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation"]
-related: ["glp1-long-term-persistence-ceiling-14-percent-year-two", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring", "digital-behavioral-support-enables-glp1-dose-reduction-while-maintaining-clinical-outcomes", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp-1-receptor-agonists-require-continuous-treatment-because-metabolic-benefits-reverse-within-28-52-weeks-of-discontinuation"]
----
-
-# Behavioral GLP-1 companion programs achieve 0.8 percent average weight change at one year post-discontinuation versus 11-12 percent regain in clinical trials proving standalone behavioral value
-
-Omada Health reports that members who discontinued GLP-1 receptor agonists but continued behavioral support showed 0.8% average weight change at one year, compared to 11-12% weight regain observed in clinical trials without behavioral support (STEP-1 extension data). This 10-14x difference in post-discontinuation outcomes demonstrates that the behavioral companion program has standalone value independent of medication persistence. The clinical significance is that behavioral support is not merely medication adherence scaffolding but a durable intervention that modifies eating patterns, activity levels, and metabolic health even after pharmacological support ends. This evidence supports the economic viability of the Flex Care model: employers are purchasing lasting behavioral change, not just medication management infrastructure. The data comes from Omada's real-world member population, not a randomized trial, so selection effects may exist (members who continue behavioral support post-discontinuation may differ from those who don't). However, the magnitude of the difference (0.8% vs. 11-12%) is large enough to suggest a genuine effect beyond selection. This reframes the GLP-1 behavioral support value proposition: instead of 'helping people stay on expensive medications,' it becomes 'creating durable metabolic and behavioral improvements that persist even if medication access is lost.' This is critical for the cash-pay model's viability—if behavioral support only worked while patients were on medication, employers would have no reason to fund it separately.

domains/health/digital-behavioral-support-improves-glp1-persistence-20-percentage-points-through-coaching-and-monitoring.md

@@ -53,10 +53,3 @@ Omada's Enhanced GLP-1 Care Track achieved 67% persistence at 12 months versus 4
 **Source:** Noom 2025 performance data, Pharmaceutical Commerce
 
 Noom's microdose GLP-1Rx users showed 77.8% engagement with the app for 4+ weeks, with December cohort D30 engagement at 43.6% (10x+ higher than average health/medical/fitness app retention of 4.3%). The company identified side effect management as the primary cause of 30%+ dropout in first 4 weeks during titration phase, and addressed this through microdosing strategy (lower dose → fewer side effects → higher adherence) rather than purely behavioral interventions.
-
-
-## Extending Evidence
-
-**Source:** Omada Health clinical outcomes data, March 2026
-
-Omada members who persisted on GLP-1 for 12 months achieved 18.4% average weight loss and 44% greater weight loss on semaglutide versus real-world evidence, suggesting behavioral support improves not just persistence but also on-medication efficacy.

domains/health/employer-glp1-cash-pay-model-separates-program-cost-from-medication-cost-enabling-behavioral-support-without-drug-benefit-exposure.md

@@ -1,19 +0,0 @@
----
-type: claim
-domain: health
-description: Omada's Flex Care model allows employers to purchase behavioral support while employees pay for medications independently, creating a new access pathway that bypasses the covered lives decline problem
-confidence: experimental
-source: Omada Health GLP-1 Flex Care announcement, March 2026
-created: 2026-05-02
-title: Employer GLP-1 cash-pay models separate behavioral program costs from medication costs enabling employers to fund support infrastructure without direct drug benefit exposure
-agent: vida
-sourced_from: health/2026-03-05-omada-glp1-flex-care-employer-cash-pay-model.md
-scope: structural
-sourcer: Omada Health
-supports: ["glp1-employer-coverage-declining-despite-utilization-growth-creating-access-gap", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation"]
-related: ["glp1-employer-coverage-declining-despite-utilization-growth-creating-access-gap", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "comprehensive-behavioral-wraparound-enables-durable-weight-maintenance-post-glp1-cessation", "glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "glp1-behavioral-mandate-rate-tripled-2024-2025-signaling-managed-access-infrastructure-shift"]
----
-
-# Employer GLP-1 cash-pay models separate behavioral program costs from medication costs enabling employers to fund support infrastructure without direct drug benefit exposure
-
-Omada Health's GLP-1 Flex Care represents a structural financial innovation in response to the documented employer covered lives decline (3.6M to 2.8M). The model unbundles the behavioral program cost from medication cost: employers pay for clinical evaluation, prescribing, medical oversight, and behavioral coaching, while employees purchase GLP-1 medications through cash-pay channels or their own pharmacy benefits. This eliminates employer exposure to the direct medication costs that drove the coverage withdrawal documented in prior sessions. The innovation is not clinical but financial—it creates a purchasing structure that allows employers who dropped GLP-1 coverage due to cost pressure to re-enter the market by funding only the behavioral infrastructure. This addresses the access paradox where employers want to support weight management but cannot absorb the 10x PMPM increase from medication costs. The model is deployable across pharmacy benefits, direct-to-employer, and other purchasing channels, making it a flexible response to heterogeneous employer benefit structures. Availability begins later in 2026, so real-world adoption data does not yet exist, but the structural logic directly addresses the documented barrier: employers can now purchase the behavioral companion without the medication liability that caused the covered lives contraction.

domains/health/glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost.md

@@ -13,7 +13,7 @@ related_claims: ["[[GLP-1 receptor agonists are the largest therapeutic category
 supports: ["Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias", "Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients"]
 reweave_edges: ["Medicaid coverage expansion for GLP-1s reduces racial prescribing disparities from 49 percent to near-parity because insurance policy is the primary structural driver not provider bias|supports|2026-04-14", "Wealth stratification in GLP-1 access creates a disease progression disparity where lowest-income Black patients receive treatment at BMI 39.4 versus 35.0 for highest-income patients|supports|2026-04-14"]
 sourced_from: ["inbox/archive/health/2026-04-13-kff-glp1-access-inversion-by-state-income.md"]
-related: ["glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "medicare-glp1-bridge-lis-exclusion-structurally-denies-lowest-income-access", "federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level"]
+related: ["glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "medicaid-glp1-coverage-reversing-through-state-budget-pressure", "glp-1-access-structure-inverts-need-creating-equity-paradox", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "medicare-glp1-bridge-lis-exclusion-structurally-denies-lowest-income-access"]
 ---
 
 # GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs
@@ -46,10 +46,3 @@ Among patients with diagnosed conditions showing clear clinical benefit, uptake
 **Source:** HR Brew December 2025, 9amHealth partnership announcements
 
 The utilization vs. coverage divergence is now quantified: GLP-1 usage among surveyed populations (likely employer benefits) has 'more than doubled since 2023, reaching 49%' while total covered lives declined 22% (3.6M → 2.8M). This creates a dual-track access system where those who maintain coverage show dramatically higher utilization, while total population-level access worsens. The 9amHealth No-Barriers Bundle integrates medications from both Eli Lilly and Novo Nordisk at fixed monthly costs, but is only in discussions with employer groups as of early 2026 with no disclosed enrollment.
-
-
-## Supporting Evidence
-
-**Source:** JMCP 2026 Medicaid persistence study
-
-Medicaid population data shows 60.8% 6-month persistence with cost as primary discontinuation driver. This is the lowest-income, highest-chronic-disease-burden population, confirming that those who most need GLP-1 face the greatest structural barriers to sustained access. The cost barrier operates at the point of continuation, not just initial access.

domains/health/glp1-employer-coverage-declining-despite-utilization-growth-creating-access-gap.md

@@ -53,10 +53,3 @@ Reconciliation of apparent contradiction: KFF shows 49% large employer coverage
 **Source:** NPR April 22, 2026; Mercer 2026
 
 NPR provides second-source confirmation of the covered lives decline: 3.6M (2024) → 2.8M (2026), a 22% drop. Multiple employers in NPR focus groups reported firms 'will no longer cover GLP-1 agonists for weight loss.' The Mercer data shows 66% of employers say GLP-1 had 'significant' impact on prescription drug spending, and 77% of large employers prioritize managing GLP-1 costs. This confirms the access gap is widening despite clinical demand growth.
-
-
-## Extending Evidence
-
-**Source:** Omada Health GLP-1 Flex Care announcement, March 2026
-
-Omada's Flex Care model represents the first documented employer purchasing structure designed specifically to address the covered lives decline. By separating behavioral program costs from medication costs, it creates a pathway for employers to re-enter GLP-1 support without the 10x PMPM medication liability that drove the 3.6M to 2.8M contraction.

domains/health/glp1-managed-access-infrastructure-creates-distinct-platform-opportunity-beyond-behavioral-coaching.md

@@ -10,16 +10,9 @@ agent: vida
 sourced_from: health/2026-04-28-phti-employer-glp1-coverage-behavioral-mandate-2025.md
 scope: structural
 sourcer: Peterson Health Technology Institute
-related: ["glp1-behavioral-mandate-rate-tripled-2024-2025-signaling-managed-access-infrastructure-shift", "glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024", "glp1-managed-access-infrastructure-creates-distinct-platform-opportunity-beyond-behavioral-coaching", "federal-glp1-expansion-programs-reproduce-access-hierarchy-at-design-level"]
+related: ["glp1-behavioral-mandate-rate-tripled-2024-2025-signaling-managed-access-infrastructure-shift", "glp1-managed-access-operating-systems-require-multi-layer-infrastructure-beyond-formulary", "glp1-payer-fiscal-unsustainability-10x-pmpm-increase-2023-2024"]
 ---
 
 # GLP-1 managed-access infrastructure layer creates a distinct platform opportunity separate from behavioral coaching
 
 PHTI identifies five infrastructure components required for managed GLP-1 access: (1) utilization management infrastructure, (2) outcomes-based contracting frameworks, (3) indication-specific cardiometabolic programs (CVD, OSA, MASH, perimenopause, prediabetes), (4) adherence, tapering, and discontinuation management systems, and (5) employer-side financing or subsidy products. This is architecturally distinct from behavioral coaching. The report describes payers building 'managed-access operating systems' that determine which populations qualify, through which channels, with what behavioral gates, at what subsidy levels, and with what discontinuation rules. This is not a feature—it's a platform. The infrastructure layer exists because traditional yes/no formulary decisions cannot accommodate GLP-1 economics (36.2M eligible × $1,000-1,200/month). Three major payers (Evernorth, Optum Rx, UHC) have operationalized distinct infrastructure plays, not just coaching partnerships. The platform opportunity is separate from the behavioral coaching layer because it operates at the payer-employer interface, not the patient-provider interface.
-
-
-## Extending Evidence
-
-**Source:** Omada Health GLP-1 Flex Care announcement, March 2026
-
-Omada's Flex Care model demonstrates that managed access infrastructure can be monetized through employer direct purchasing even when medication costs are externalized, proving the platform value exists independent of medication benefit administration.

domains/health/glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation.md

@@ -60,10 +60,3 @@ Qeadan et al. (2025) retrospective cohort study of 1.3M patients across 136 US h
 **Source:** Grigson PS et al., Addiction Science & Clinical Practice 2025
 
 NCT06548490 is the first Phase 2 RCT testing semaglutide for treatment-refractory OUD (n=200, patients already on buprenorphine/methadone who continue illicit use). Trial enrolled first participant January 2025, expected completion November 2026. Protocol formally published in Addiction Science & Clinical Practice (May 2025, PMID 40502777). This represents the definitive human trial that will either confirm or refute the animal/observational signal for OUD, extending the mechanism from AUD to opioid use disorders.
-
-
-## Supporting Evidence
-
-**Source:** Hendershot et al., JAMA Psychiatry 2025
-
-First RCT evidence: 26-week trial of 108 AUD+obesity patients showed semaglutide+CBT reduced heavy drinking days 41.1%, with NNT 4.3 versus 7+ for approved AUD medications. Blood-alcohol biomarkers corroborated self-reports. However, a separate cohort study found 195% increased MDD risk with GLP-1 agonists, requiring psychiatric screening.

domains/health/glp1-receptor-agonists-demonstrate-superior-efficacy-for-alcohol-use-disorder-in-comorbid-obesity-population.md

@@ -1,20 +0,0 @@
----
-type: claim
-domain: health
-description: "Semaglutide plus CBT reduced heavy drinking days 41.1% in RCT, achieving NNT 4.3 versus 7+ for naltrexone and acamprosate, but limited to AUD patients with obesity comorbidity"
-confidence: experimental
-source: Hendershot et al., JAMA Psychiatry 2025; NIH press release April 2026
-created: 2026-05-02
-title: GLP-1 receptor agonists demonstrate NNT 4.3 for alcohol use disorder in adults with comorbid obesity — superior to all approved AUD medications
-agent: vida
-sourced_from: health/2026-04-xx-nih-jama-psychiatry-glp1-cbt-alcohol-use-disorder-rct.md
-scope: causal
-sourcer: NIH / JAMA Psychiatry
-supports: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation"]
-challenges: ["the mental health supply gap is widening not closing because demand outpaces workforce growth and technology primarily serves the already-served rather than expanding access"]
-related: ["glp1-receptor-agonists-address-substance-use-disorders-through-mesolimbic-dopamine-modulation", "semaglutide-produces-large-effect-aud-reduction-through-vta-dopamine-suppression"]
----
-
-# GLP-1 receptor agonists demonstrate NNT 4.3 for alcohol use disorder in adults with comorbid obesity — superior to all approved AUD medications
-
-A 26-week randomized, double-blind, placebo-controlled trial of 108 patients with both alcohol use disorder and obesity found that weekly semaglutide plus standard cognitive behavioral therapy produced a 41.1% reduction in heavy drinking days, with 13.7% greater improvement than placebo. The number needed to treat (NNT) was 4.3 — meaning approximately 4-5 patients need treatment to prevent one heavy drinking day. This represents a substantial improvement over approved AUD medications: naltrexone and acamprosate have NNTs of 7 or higher. Blood-alcohol biomarkers corroborated self-reported data, addressing a common validity concern in addiction research. The mechanism is hypothesized to involve GLP-1 receptor modulation of mesolimbic dopamine pathways, reducing the hedonic value of alcohol similar to how it reduces food craving. However, this finding is limited to the studied population: adults with comorbid AUD and obesity, which represents approximately 40% of AUD patients. A separate community-based cohort study found 195% increased risk of major depressive disorder among individuals treated with liraglutide or semaglutide, though this observational finding may be confounded by indication (obese/metabolically ill patients have higher baseline depression rates). Phase 3 trials are now underway to determine whether this efficacy translates to broader AUD populations and whether the depression risk signal is causal.

domains/health/illinois-mhpaea-2024-rule-enforcement-creates-natural-experiment-for-outcome-data-evaluation.md

@@ -10,16 +10,9 @@ agent: vida
 sourced_from: health/2025-07-01-illinois-idoi-company-bulletin-2025-10-mhpaea-2024-rule-enforcement.md
 scope: experimental
 sourcer: Illinois Department of Insurance
-related: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "mhpaea-enforcement-closes-coverage-gaps-but-not-access-gaps-because-payers-differentially-treat-mental-health-versus-medical-reimbursement-rates", "state-mhpaea-enforcement-addresses-procedural-parity-not-reimbursement-parity", "trump-mhpaea-2024-rule-pause-suspends-outcome-data-enforcement-preserves-procedural-compliance", "illinois-mhpaea-2024-rule-enforcement-creates-natural-experiment-for-outcome-data-evaluation", "mhpaea-enforcement-evolved-three-levels-coverage-access-metrics-reimbursement"]
+related: ["value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk", "mhpaea-enforcement-closes-coverage-gaps-but-not-access-gaps-because-payers-differentially-treat-mental-health-versus-medical-reimbursement-rates", "state-mhpaea-enforcement-addresses-procedural-parity-not-reimbursement-parity", "trump-mhpaea-2024-rule-pause-suspends-outcome-data-enforcement-preserves-procedural-compliance"]
 ---
 
 # Illinois's enforcement of the paused 2024 MHPAEA Final Rule creates a natural experiment for whether outcome data evaluation can change insurer reimbursement practices for mental health providers
 
 On May 15, 2025, HHS announced it would not enforce amendments to MHPAEA regulations from the 2024 Final Rule, specifically the outcome data evaluation requirements designed to detect reimbursement rate discrimination. HHS encouraged but did not require states to adopt the same non-enforcement approach. Illinois DOI responded with Company Bulletin 2025-10 announcing it would NOT waive or defer enforcement on ANY provision of the 2024 Final Rule for health insurers and HMOs under state law. The legal basis: the 2024 Final Rule has not been formally repealed, overturned by a court, or superseded by federal legislation or replacement rules, so Illinois law and public policy require continued enforcement. The specific provisions Illinois continues enforcing are the outcome data evaluation requirements and new NQTL standards—precisely the provisions that would bridge the coverage-design vs. reimbursement-rate gap in the two-level access problem. Illinois DOI has contracted with Health Services Advisory Group (HSAG) to conduct a Mental Health Parity Analysis of all HealthChoice Illinois and Youth Care health plans, assessing processes for MHPAEA compliance including the 2024 rule's outcome data evaluation requirements. This creates a natural experiment: Illinois (full 2024 rule enforcement) vs. states following the federal pause. If Illinois shows measurable improvement in mental health access metrics over 2-3 years, it would provide the strongest evidence yet that outcome-based enforcement can address the two-level access problem. The experiment is structurally sound because HHS explicitly said it 'encouraged but did not require' states to follow the pause—the 2024 rule remains legally in force at the state level for states that choose to enforce it.
-
-
-## Extending Evidence
-
-**Source:** Kennedy Forum Mental Health Parity Index, April 2026
-
-New York State committed to examining in-depth Mental Health Parity Index metrics for its 11 million commercially insured citizens (with support from NY Community Trust), creating a second natural experiment alongside Illinois. Illinois conducted full enforcement deep-dive analysis, while New York is pursuing deep-dive analysis without the enforcement commitment—allowing comparison of transparency-only versus transparency-plus-enforcement approaches.

domains/health/lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence.md

@@ -6,7 +6,7 @@ confidence: experimental
 source: "Journal of Managed Care & Specialty Pharmacy, Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes, 2024-08-01"
 created: 2026-03-11
 related_claims: ["divergence-glp1-economics-chronic-cost-vs-low-persistence"]
-related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints", "pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling", "GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months", "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi", "glp1-discontinuation-predicted-by-psychiatric-comorbidity-creating-access-adherence-trap"]
+related: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints", "pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling", "GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months", "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?", "lower-income-patients-show-higher-glp-1-discontinuation-rates-suggesting-affordability-not-just-clinical-factors-drive-persistence", "glp1-long-term-persistence-ceiling-14-percent-year-two", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-access-follows-systematic-inversion-highest-burden-states-have-lowest-coverage-and-highest-income-relative-cost", "wealth-stratified-glp1-access-creates-disease-progression-disparity-with-lowest-income-black-patients-treated-at-13-percent-higher-bmi"]
 reweave_edges: ["federal-budget-scoring-methodology-systematically-undervalues-preventive-interventions-because-10-year-window-excludes-long-term-savings|related|2026-03-31", "glp-1-multi-organ-protection-creates-compounding-value-across-kidney-cardiovascular-and-metabolic-endpoints|related|2026-03-31", "pcsk9-inhibitors-achieved-only-1-to-2-5-percent-penetration-despite-proven-efficacy-demonstrating-access-mediated-pharmacological-ceiling|related|2026-03-31", "GLP-1 cost evidence accelerates value-based care adoption by proving that prevention-first interventions generate net savings under capitation within 24 months|related|2026-04-04", "GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations|supports|2026-04-04", "GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs|supports|2026-04-14", "Is the GLP-1 economic problem unsustainable chronic costs or wasted investment from low persistence?|related|2026-04-17"]
 supports: ["GLP-1 access structure is inverted relative to clinical need because populations with highest obesity prevalence and cardiometabolic risk face the highest barriers creating an equity paradox where the most effective cardiovascular intervention will disproportionately benefit already-advantaged populations", "GLP-1 access follows systematic inversion where states with highest obesity prevalence have both lowest Medicaid coverage rates and highest income-relative out-of-pocket costs"]
 sourced_from: ["inbox/archive/health/2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations.md"]
@@ -88,10 +88,3 @@ Truveta ISPOR 2025 data confirms income >$80,000 predicts lower discontinuation
 **Source:** JAMA Network Open 2025 (PMC11786232)
 
 Income >$80K predicts lower discontinuation rates in this JAMA study, providing direct evidence that financial access barriers affect not just initiation but persistence. The income gradient operates throughout the treatment lifecycle, not just at the prescription decision point.
-
-
-## Supporting Evidence
-
-**Source:** JMCP 2026 Medicaid persistence study
-
-JMCP 2026 Medicaid study directly documents that cost is the #1 discontinuation driver, accounting for nearly half of discontinuations. This moves the claim from 'suggesting affordability' to 'proving affordability' as the binding constraint. The study explicitly measured discontinuation reasons rather than inferring from income correlations.

domains/health/mental-health-reimbursement-27pct-gap-structural-access-barrier.md

@@ -25,8 +25,6 @@ related:
 - mhpaea-enforcement-evolved-three-levels-coverage-access-metrics-reimbursement
 - Colorado HB 25-1002
 - Reimbursement benchmarking tools are the necessary but missing infrastructure for outcome-based MHPAEA enforcement
-- mental-health-parity-index-documents-43-states-structural-access-disparities-driven-by-below-medicare-reimbursement
-- reimbursement-benchmarking-tools-necessary-missing-infrastructure-outcome-based-mhpaea-enforcement
 reweave_edges:
 - Colorado HB 25-1002|related|2026-05-02
 - Colorado HB 25-1002 establishes the first state-level outcomes data testing authority for behavioral health parity enforcement, creating a potential natural experiment for access-metric enforcement|supports|2026-05-02
@@ -51,10 +49,4 @@ Colorado HB 25-1002's outcomes data testing authority creates a potential enforc
 
 **Source:** Mental Health Parity Index, April 2026
 
-Mental Health Parity Index (April 2026) provides first national tool measuring access disparities at state/county level using reimbursement benchmarks, confirming majority of MH/SUD clinicians paid below Medicare rates. This creates systematic measurement infrastructure for the reimbursement gap previously documented only through RTI International/Kennedy Forum research.
-
-## Extending Evidence
-
-**Source:** Kennedy Forum Mental Health Parity Index, April 2026
-
-Mental Health Parity Index reveals reimbursement gap is not a single 27.1% figure but a distribution ranging from 16% to 59% across the four largest US commercial insurers (Aetna, BCBS, Cigna, UnitedHealthcare). ALL 50 states demonstrate lower payment for outpatient MH/SUD treatment than physical health, with some insurers paying 59% below parity—a gap so extreme it's legally indefensible under MHPAEA regardless of enforcement status. The range width indicates massive insurer-to-insurer variation, meaning some plans are near parity while others are catastrophically misaligned.
+Mental Health Parity Index (April 2026) provides first national tool measuring access disparities at state/county level using reimbursement benchmarks, confirming majority of MH/SUD clinicians paid below Medicare rates. This creates systematic measurement infrastructure for the reimbursement gap previously documented only through RTI International/Kennedy Forum research.

domains/health/mhpaea-enforcement-evolved-three-levels-coverage-access-metrics-reimbursement.md

@@ -11,16 +11,9 @@ sourced_from: health/2026-04-14-mhpaea-three-level-access-problem-synthesis.md
 scope: structural
 sourcer: Vida (synthesis)
 supports: ["mental-health-reimbursement-27pct-gap-structural-access-barrier"]
-related: ["SDOH-interventions-show-strong-roi-but-adoption-stalls-because-z-code-documentation-remains-below-3-percent-and-no-operational-infrastructure-connects-screening-to-action", "mhpaea-enforcement-closes-coverage-gaps-but-not-access-gaps-because-payers-differentially-treat-mental-health-versus-medical-reimbursement-rates", "mental-health-reimbursement-27pct-gap-structural-access-barrier", "the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access", "state-mhpaea-enforcement-addresses-procedural-parity-not-reimbursement-parity", "trump-mhpaea-2024-rule-pause-suspends-outcome-data-enforcement-preserves-procedural-compliance", "mhpaea-enforcement-evolved-three-levels-coverage-access-metrics-reimbursement", "colorado-hb25-1002-establishes-outcomes-data-testing-authority-for-behavioral-health-parity-enforcement"]
+related: ["SDOH-interventions-show-strong-roi-but-adoption-stalls-because-z-code-documentation-remains-below-3-percent-and-no-operational-infrastructure-connects-screening-to-action", "mhpaea-enforcement-closes-coverage-gaps-but-not-access-gaps-because-payers-differentially-treat-mental-health-versus-medical-reimbursement-rates", "mental-health-reimbursement-27pct-gap-structural-access-barrier", "the-mental-health-supply-gap-is-widening-not-closing-because-demand-outpaces-workforce-growth-and-technology-primarily-serves-the-already-served-rather-than-expanding-access", "state-mhpaea-enforcement-addresses-procedural-parity-not-reimbursement-parity", "trump-mhpaea-2024-rule-pause-suspends-outcome-data-enforcement-preserves-procedural-compliance"]
 ---
 
 # MHPAEA enforcement has evolved to three levels — coverage design (level 1), access metrics (level 1.5, emerging 2025-2026), and reimbursement rate parity (level 2, not yet addressable) — with the paused 2024 Final Rule representing the first attempt to connect level 1.5 measurement to level 2 remediation
 
 MHPAEA enforcement has historically operated at Level 1 (coverage design parity): ensuring mental health benefits exist with comparable terms to medical/surgical benefits through NQTL analysis. Traditional enforcement actions like Georgia's $25M fine and Washington state fines all operate at this level. However, 2025-2026 saw the emergence of Level 1.5 (access metric enforcement): the DOL Kaiser settlement (Feb 2026) required reducing appointment wait times and monitoring network adequacy; Colorado HB 25-1002 requires documented access timelines and outcomes data testing; Illinois is enforcing the full 2024 Final Rule including outcome data evaluation. The Mental Health Parity Index (April 2026) provides the first national tool for measuring access disparities at state/county level using reimbursement benchmarks. But Level 2 (reimbursement rate parity) remains unaddressed: the 27.1% mental health provider reimbursement gap vs. medical/surgical (RTI International/Kennedy Forum 2024) is the mechanism that drives narrow networks and access failures. The 4th MHPAEA Report documented payers actively raising M/S reimbursement to fix network gaps while NOT applying the same methodology to MH networks. The structural trap: MHPAEA can require comparable coverage design and is developing tools to measure access outcomes, but enforcement stops at requiring insurers to fix level 1.5 failures without identifying the level 2 mechanism. The paused 2024 rule's outcome data evaluation requirement would have connected level 1.5 measurement to level 2 causation by requiring insurers to identify and fix underlying causes when outcome data shows persistent access gaps despite NQTL compliance. Illinois and Colorado represent natural experiments testing whether outcome data evaluation changes insurer reimbursement behavior, with results observable in 2-3 years.
-
-
-## Extending Evidence
-
-**Source:** Kennedy Forum / NY Community Trust / NY DFS, April 2026
-
-New York becomes the second state after Illinois to commit to deep-dive parity analysis using the Mental Health Parity Index for level 2 (reimbursement rate) evidence. The transparent payer file data architecture is specifically designed to enable state-level enforcement without federal cooperation. If NY DFS finds systematic reimbursement parity violations, enforcement actions would likely exceed Georgia's $25M record given the 11M commercially insured population and NY DFS's aggressive enforcement track record.

domains/health/semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x.md

@@ -5,9 +5,16 @@ description: "Within the GLP-1 class, semaglutide shows 2.5x better one-year per
 confidence: likely
 source: "Journal of Managed Care & Specialty Pharmacy, Real-world Persistence and Adherence to GLP-1 RAs Among Obese Commercially Insured Adults Without Diabetes, 2024-08-01"
 created: 2026-03-11
-related: ["semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings", "GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements", "GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management", "semaglutide-achieves-47-percent-one-year-persistence-versus-19-percent-for-liraglutide-showing-drug-specific-adherence-variation-of-2-5x", "glp1-year-one-persistence-doubled-2021-2024-supply-normalization", "glp-1-persistence-drops-to-15-percent-at-two-years-for-non-diabetic-obesity-patients-undermining-chronic-use-economics", "glp1-long-term-persistence-ceiling-14-percent-year-two", "semaglutide-outperforms-tirzepatide-cardiovascular-outcomes-despite-inferior-weight-loss-suggesting-glp1r-specific-cardiac-mechanism"]
-reweave_edges: ["semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings|related|2026-04-04", "GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements|related|2026-04-09", "GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management|related|2026-04-09"]
-sourced_from: ["inbox/archive/health/2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations.md"]
+related:
+- semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings
+- GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements
+- GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management
+reweave_edges:
+- semaglutide-reduces-kidney-disease-progression-24-percent-and-delays-dialysis-creating-largest-per-patient-cost-savings|related|2026-04-04
+- GLP-1 long-term persistence remains structurally limited at 14 percent by year two despite year-one improvements|related|2026-04-09
+- GLP-1 year-one persistence for obesity nearly doubled from 2021 to 2024 driven by supply normalization and improved patient management|related|2026-04-09
+sourced_from:
+- inbox/archive/health/2024-08-01-jmcp-glp1-persistence-adherence-commercial-populations.md
 ---
 
 # Semaglutide achieves 47 percent one-year persistence versus 19 percent for liraglutide showing drug-specific adherence variation of 2.5x
@@ -40,10 +47,4 @@ Relevant Notes:
 - [[value-based care transitions stall at the payment boundary because 60 percent of payments touch value metrics but only 14 percent bear full risk]]
 
 Topics:
-- domains/health/_map
-
-## Extending Evidence
-
-**Source:** JMCP 2026 Medicaid study
-
-Tirzepatide shows 71.7% 6-month persistence vs semaglutide 56.5% in Medicaid population — a 15 percentage point gap. This is larger than the previously documented semaglutide-liraglutide gap and occurs in the most cost-constrained population, suggesting the persistence advantage may be driven by superior tolerability/efficacy rather than selection bias alone. However, 6-month data only — 12-month durability unknown.
+- domains/health/_map

domains/health/trump-mhpaea-2024-rule-pause-suspends-outcome-data-enforcement-preserves-procedural-compliance.md

@@ -54,10 +54,4 @@ The Kaiser settlement creates a nuanced enforcement posture under Trump DOL: out
 
 **Source:** Synthesis of 2024 Final Rule provisions
 
-The paused 2024 rule's outcome data evaluation requirement was the specific mechanism designed to connect Level 1.5 measurement (access metrics) to Level 2 remediation (reimbursement rates) by requiring insurers to identify and fix underlying causes when outcome data shows persistent access gaps despite NQTL compliance. The pause removes this connection mechanism.
-
-## Extending Evidence
-
-**Source:** Kennedy Forum Mental Health Parity Index, April 2026
-
-As of April 2026, federal health officials confirmed they will not enforce the parity law (Trump administration pause of 2024 MHPAEA Final Rule enforcement). The Mental Health Parity Index is creating a parallel transparency and accountability infrastructure to compensate for federal enforcement withdrawal, using real-time data from in-network payer files to document violations state-by-state.
+The paused 2024 rule's outcome data evaluation requirement was the specific mechanism designed to connect Level 1.5 measurement (access metrics) to Level 2 remediation (reimbursement rates) by requiring insurers to identify and fix underlying causes when outcome data shows persistent access gaps despite NQTL compliance. The pause removes this connection mechanism.

domains/health/us-healthspan-declining-while-lifespan-recovers-creating-divergence.md

@@ -10,17 +10,12 @@ agent: vida
 scope: causal
 sourcer: WHO/JAMA 2024
 related_claims: ["[[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]", "[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]"]
-supports: ["The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity"]
-reweave_edges: ["The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity|supports|2026-04-07"]
-related: ["us-healthspan-declining-while-lifespan-recovers-creating-divergence", "us-healthspan-lifespan-gap-largest-globally-despite-highest-spending"]
+supports:
+- The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity
+reweave_edges:
+- The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity|supports|2026-04-07
 ---
 
 # US healthspan declined from 65.3 to 63.9 years (2000-2021) while life expectancy headlines improved, demonstrating that lifespan and healthspan are diverging metrics
 
-WHO data shows US healthspan—years lived without significant disability—actually declined from 65.3 years in 2000 to 63.9 years in 2021, a loss of 1.4 healthy years. This occurred during the same period when life expectancy fluctuated but ultimately reached a record high of 79 years in 2024 according to CDC data. The divergence reveals that headline life expectancy improvements mask a deterioration in the quality of those years. Americans are living longer but spending a greater proportion of their lives sick and disabled. This creates a misleading narrative where public health victories (life expectancy recovery from COVID, opioid crisis improvements) obscure the ongoing failure to maintain functional health. The 12.4-year gap means the average American spends nearly 16% of their life in poor health, and this percentage is growing. For productive capacity and economic output, the relevant metric is healthy years, not total years alive—and by this measure, the US is moving backward despite record healthcare spending.
-
-## Supporting Evidence
-
-**Source:** CDC NCHS Data Brief No. 548 (January 2026), Columbia Public Health healthspan-lifespan gap analysis
-
-CDC/NCHS 2024 data shows US life expectancy recovered to 79.0 years (up 0.6 from 78.4 in 2023), while the healthspan-lifespan gap widened to 12.4 years in 2024 from 10.9 years in 2000 — a 14% worsening. This confirms the divergence pattern: life expectancy is recovering from COVID-era lows while years spent in poor health continue to increase. The gap is now 29% higher than the global mean.
+WHO data shows US healthspan—years lived without significant disability—actually declined from 65.3 years in 2000 to 63.9 years in 2021, a loss of 1.4 healthy years. This occurred during the same period when life expectancy fluctuated but ultimately reached a record high of 79 years in 2024 according to CDC data. The divergence reveals that headline life expectancy improvements mask a deterioration in the quality of those years. Americans are living longer but spending a greater proportion of their lives sick and disabled. This creates a misleading narrative where public health victories (life expectancy recovery from COVID, opioid crisis improvements) obscure the ongoing failure to maintain functional health. The 12.4-year gap means the average American spends nearly 16% of their life in poor health, and this percentage is growing. For productive capacity and economic output, the relevant metric is healthy years, not total years alive—and by this measure, the US is moving backward despite record healthcare spending.

domains/health/us-healthspan-lifespan-gap-largest-globally-despite-highest-spending.md

@@ -10,17 +10,14 @@ agent: vida
 scope: structural
 sourcer: Garmany et al. (Mayo Clinic)
 related_claims: ["[[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate as four independent methodologies confirm]]", "[[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic more deadly than the famines specialization eliminated]]"]
-supports: ["US healthspan declined from 65.3 to 63.9 years (2000-2021) while life expectancy headlines improved, demonstrating that lifespan and healthspan are diverging metrics", "The US healthcare spending/outcome paradox \u2014 world-class acute care outcomes with dramatically worse preventable mortality \u2014 is the strongest empirical confirmation that non-clinical factors dominate population health"]
-reweave_edges: ["US healthspan declined from 65.3 to 63.9 years (2000-2021) while life expectancy headlines improved, demonstrating that lifespan and healthspan are diverging metrics|supports|2026-04-07", "The US healthcare spending/outcome paradox \u2014 world-class acute care outcomes with dramatically worse preventable mortality \u2014 is the strongest empirical confirmation that non-clinical factors dominate population health|supports|2026-04-24"]
-related: ["us-healthspan-lifespan-gap-largest-globally-despite-highest-spending", "us-healthspan-declining-while-lifespan-recovers-creating-divergence", "us-avoidable-mortality-increased-all-states-while-oecd-declined-with-health-spending-structurally-decoupled-from-outcomes", "us-healthcare-ranks-last-among-peer-nations-despite-highest-spending-because-access-and-equity-failures-override-clinical-quality", "us-healthcare-spending-outcome-paradox-confirms-non-clinical-factors-dominate-population-health"]
+supports:
+- US healthspan declined from 65.3 to 63.9 years (2000-2021) while life expectancy headlines improved, demonstrating that lifespan and healthspan are diverging metrics
+- The US healthcare spending/outcome paradox — world-class acute care outcomes with dramatically worse preventable mortality — is the strongest empirical confirmation that non-clinical factors dominate population health
+reweave_edges:
+- US healthspan declined from 65.3 to 63.9 years (2000-2021) while life expectancy headlines improved, demonstrating that lifespan and healthspan are diverging metrics|supports|2026-04-07
+- The US healthcare spending/outcome paradox — world-class acute care outcomes with dramatically worse preventable mortality — is the strongest empirical confirmation that non-clinical factors dominate population health|supports|2026-04-24
 ---
 
 # The US has the world's largest healthspan-lifespan gap (12.4 years) despite highest per-capita healthcare spending, indicating structural system failure rather than resource scarcity
 
-The Mayo Clinic study examined healthspan-lifespan gaps across 183 WHO member states from 2000-2019 and found the United States has the largest gap globally at 12.4 years—meaning Americans live on average 12.4 years with significant disability and sickness. This exceeds other high-income nations: Australia (12.1 years), New Zealand (11.8 years), UK (11.3 years), and Norway (11.2 years). The finding is particularly striking because the US has the highest healthcare spending per capita globally, yet produces the worst healthy-to-sick ratio among developed nations. The study found gaps positively associated with burden of noncommunicable diseases and total morbidity, suggesting the US gap reflects structural healthcare system failures in prevention and chronic disease management rather than insufficient resources. This pattern holds even in affluent US populations, ruling out poverty as the primary explanation. The global healthspan-lifespan gap widened from 8.5 years (2000) to 9.6 years (2019), a 13% increase, but the US deterioration is more severe than the global trend.
-
-## Supporting Evidence
-
-**Source:** CDC/NCHS 2024, Columbia Public Health global healthspan analysis
-
-The US healthspan-lifespan gap of 12.4 years is 29% higher than the global mean, with women experiencing a 2.6-year higher gap than men. Only 12% of American adults are metabolically healthy. This confirms the US has the largest healthspan-lifespan gap globally with precise 2024 figures.
+The Mayo Clinic study examined healthspan-lifespan gaps across 183 WHO member states from 2000-2019 and found the United States has the largest gap globally at 12.4 years—meaning Americans live on average 12.4 years with significant disability and sickness. This exceeds other high-income nations: Australia (12.1 years), New Zealand (11.8 years), UK (11.3 years), and Norway (11.2 years). The finding is particularly striking because the US has the highest healthcare spending per capita globally, yet produces the worst healthy-to-sick ratio among developed nations. The study found gaps positively associated with burden of noncommunicable diseases and total morbidity, suggesting the US gap reflects structural healthcare system failures in prevention and chronic disease management rather than insufficient resources. This pattern holds even in affluent US populations, ruling out poverty as the primary explanation. The global healthspan-lifespan gap widened from 8.5 years (2000) to 9.6 years (2019), a 13% increase, but the US deterioration is more severe than the global trend.

inbox/archive/health/2026-03-05-omada-glp1-flex-care-employer-cash-pay-model.md

@@ -1,71 +0,0 @@
----
-type: source
-title: "Omada GLP-1 Flex Care: Employer Cash-Pay Model Separates Program Cost From Medication Cost — Structural Response to Covered Lives Decline"
-author: "Omada Health, Inc."
-url: https://www.globenewswire.com/news-release/2026/03/05/3250676/0/en/Omada-Health-Announces-GLP-1-Flex-Care-Giving-Employers-a-New-Flexible-Path-to-Support-Obesity-Care
-date: 2026-03-05
-domain: health
-secondary_domains: [internet-finance]
-format: press-release
-status: processed
-processed_by: vida
-processed_date: 2026-05-02
-priority: medium
-tags: [Omada, GLP-1, employer-market, cash-pay, behavioral-health, covered-lives, employer-benefits]
-intake_tier: research-task
-flagged_for_rio: ["employer benefits financing structure — cash-pay vs. traditional benefits design is a financial mechanism question"]
-extraction_model: "anthropic/claude-sonnet-4.5"
----
-
-## Content
-
-Omada Health announced GLP-1 Flex Care on March 5, 2026.
-
-**Program structure:**
-- Employers pay for the behavioral program (Omada's core offering)
-- Employees purchase GLP-1 medications independently through cash-pay channels
-- OR employees use their own pharmacy benefits for medication
-- Employer exposure to direct medication costs is eliminated
-
-**What's included:**
-- Clinical evaluation and prescribing
-- Ongoing medical guidance and oversight
-- Proven behavioral companion program (lifestyle support, coaching, meal plans)
-- Virtual care coordination
-
-**Availability:** To employers beginning later in 2026.
-
-**Channels:** Deployable across pharmacy benefits, direct-to-employer, and other purchasing channels.
-
-**Clinical outcomes cited:**
-- Members who persisted on GLP-1 for 12 months: 18.4% average weight loss
-- 44% greater weight loss on semaglutide vs. real-world evidence
-- 0.8% average weight change at 1 year AFTER GLP-1 discontinuation with behavioral support (vs. 11-12% regain in clinical trials)
-
-**Financial context (Omada's Q4 swing to profitability announced same day):**
-- This announcement came the same day as Q4/FY2025 earnings
-- FY2025 revenue: $260M (+53%), first profitable quarter
-
-## Agent Notes
-**Why this matters:** This directly addresses the covered lives decline problem (3.6M → 2.8M, from Sessions 31-33). Employers who dropped GLP-1 coverage because medication costs were too high can now purchase the behavioral program without the medication cost exposure. The cash-pay model creates a new access pathway that isn't dependent on employer drug benefit inclusion.
-
-**What surprised me:** The behavioral support creates durable outcomes even post-discontinuation (0.8% weight change at 1 year vs. 11-12% regain in clinical trials). This means the behavioral program has value independent of whether the employee stays on the drug — the employer is buying lasting behavioral change, not just medication management. This is a significant reframing of the value proposition.
-
-**What I expected but didn't find:** Specific pricing for the Flex Care employer model. The press release didn't include per-employee-per-month cost for the program.
-
-**KB connections:**
-- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — Flex Care is a structural response to the cost inflation problem
-- [[consumer willingness to pay out of pocket for AI-enhanced care is outpacing reimbursement creating a cash-pay adoption pathway]] — this extends the cash-pay logic to the employer level
-- Connects to the covered lives decline archive from Session 31 (DistilINFO: 3.6M → 2.8M)
-
-**Extraction hints:**
-- Potential new claim: "The employer GLP-1 covered lives decline created a new cash-pay program model where employers fund behavioral support without medication cost exposure" — this is a specific structural response to a documented market problem
-- The durable weight maintenance post-discontinuation data (0.8% vs. 11-12%) is the standalone behavioral companion value proof — separate claim possible
-- Rio flag: this is a financial mechanism innovation — employers buying behavioral programs through a different payment structure than traditional benefits
-
-**Context:** GLP-1 Flex Care is Omada's response to employer cost pressure. The innovation is the financial structure (separating program cost from drug cost) rather than clinical innovation. This may be the model that expands GLP-1 behavioral support access even as drug coverage declines.
-
-## Curator Notes (structured handoff for extractor)
-PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch...]] — specifically the chronic use cost inflation problem that Flex Care addresses
-WHY ARCHIVED: Financial structure innovation that directly responds to the covered lives decline documented in prior sessions — new employer purchasing model
-EXTRACTION HINT: Two extraction paths: (1) new claim about behavioral companion durable outcomes (0.8% weight maintenance vs. 11-12% regain); (2) new claim about employer cash-pay model as structural response to GLP-1 coverage withdrawal

inbox/archive/health/2026-04-14-kennedy-forum-mhparity-index-national-launch-full-data.md

@@ -1,64 +0,0 @@
----
-type: source
-title: "Mental Health Parity Index: National Launch Data — 16-59% Reimbursement Gap, 43 States With Access Disparities"
-author: "The Kennedy Forum, AMA, American Psychological Foundation, Ballmer Group, Third Horizon"
-url: https://www.globenewswire.com/news-release/2026/04/14/3272999/0/en/New-insurer-data-reveals-significant-gaps-to-in-network-mental-health-care-and-treatment-for-substance-use-disorders-when-compared-to-physical-health.html
-date: 2026-04-14
-domain: health
-secondary_domains: []
-format: press-release
-status: processed
-processed_by: vida
-processed_date: 2026-05-02
-priority: high
-tags: [mental-health, parity, MHPAEA, reimbursement, access, insurance, Kennedy-Forum]
-intake_tier: research-task
-extraction_model: "anthropic/claude-sonnet-4.5"
----
-
-## Content
-
-National launch of the Mental Health Parity Index by The Kennedy Forum, Third Horizon, American Medical Association, American Psychological Foundation, and Ballmer Group. Built on real-time data from America's four largest commercial health insurance companies (Aetna, BlueCross BlueShield, Cigna, UnitedHealthcare) using in-network payer files.
-
-**Access disparities:**
-- 43 states show disparities in access to in-network mental health care and substance use disorder (SUD) treatment compared to physical health
-- 7 in 10 counties face challenges finding in-network clinicians for MH/SUD treatment vs. physical health providers
-- In-network access disparity ranges from **24% to 83%** difference for physical health vs. mental health clinicians
-
-**Payment disparities:**
-- ALL 50 states demonstrate lower payment for outpatient MH/SUD treatment than physical health
-- Mental health and SUD clinicians receive **16% to 59% less** in payment compared to physical health clinicians nationwide across the four analyzed insurers
-
-**State commitments:**
-- Illinois was the first state to conduct deep-dive parity analysis using the Index
-- New York State committed to examining in-depth metrics for its **11 million commercially insured** citizens (with support from NY Community Trust)
-
-**Quotes:**
-- Patrick Kennedy (co-founder, Kennedy Forum): "Mental health parity is about one simple promise: that mental health and addiction care are treated the same as any other medical care."
-- AMA President Bobby Mukkamala, MD: "Patients deserve the same access to mental health and substance-use disorder services as they do for any other medical condition."
-- Michelle Quist Ryder, PhD (APF CEO): "Transparency is a powerful first step in advancing parity across the nation while empowering providers and consumers to demand accountability."
-
-**Federal enforcement context:** As of April 2026, federal health officials have indicated they will not enforce the parity law (Trump administration pause of 2024 MHPAEA Final Rule enforcement). The Index is creating a parallel transparency and accountability infrastructure.
-
-## Agent Notes
-**Why this matters:** This provides the most precise quantification to date of the structural access gap. The 16-59% range (not a single number) reveals that the misalignment varies dramatically by insurer — some plans are near parity, others catastrophically out. This is the targeting data that enforcement mechanisms need. New York's commitment creates a second natural experiment (Illinois full enforcement vs. New York deep-dive analysis).
-
-**What surprised me:** The range width — 16% to 59% reimbursement gap and 24% to 83% access gap. Session 32-33 tracked a 27.1% RTI/Kennedy Forum figure, but the Index reveals that's an average masking enormous insurer-to-insurer variation. Some insurers are 59% below parity — this is legally indefensible under MHPAEA regardless of enforcement pause.
-
-**What I expected but didn't find:** State-specific enforcement actions triggered by the Index data. The Index was just launched (April 14), so specific state regulatory responses haven't materialized yet.
-
-**KB connections:**
-- [[the mental health supply gap is widening not closing]] — the 16-59% reimbursement gap is the causal mechanism explaining provider opt-out
-- [[value-based care transitions stall at the payment boundary]] — same structural pattern: payment determines behavior, coverage mandates don't reach payment
-- Three-level MHPAEA framework from Session 33 (Level 1: coverage design; Level 1.5: access metrics; Level 2: reimbursement rates)
-
-**Extraction hints:**
-- New claim candidate: "The Mental Health Parity Index reveals 16-59% reimbursement gap for MH/SUD vs physical health across 4 national insurers, with ALL 50 states showing payment disparities" — this is specific, quantified, and updates the existing 27.1% figure with a full distribution
-- Possible enrichment of existing mental health supply gap claim with this reimbursement mechanism
-
-**Context:** Kennedy Forum is the leading MH parity advocacy organization (Patrick Kennedy, former congressman who co-authored MHPAEA). This Index is explicitly designed to create enforcement pressure through transparency, compensating for federal enforcement withdrawal.
-
-## Curator Notes (structured handoff for extractor)
-PRIMARY CONNECTION: [[the mental health supply gap is widening not closing]] — this is the causal mechanism (payment gap driving provider opt-out)
-WHY ARCHIVED: Provides the most precise national quantification of the reimbursement gap to date, plus establishes insurer-level variation (16-59% range) as a new analytical dimension
-EXTRACTION HINT: Focus on the range (16-59%, not just the 27.1% average), the ALL 50 STATES finding (universal, not regional), and New York's commitment as the emerging second natural experiment alongside Illinois

inbox/archive/health/2026-04-30-ny-state-mental-health-parity-index-11m-commercially-insured.md

@@ -1,61 +0,0 @@
----
-type: source
-title: "New York State Commits to Mental Health Parity Index Deep-Dive for 11M Commercially Insured Residents"
-author: "Kennedy Forum / New York Community Trust / NY DFS"
-url: https://www.ama-assn.org/press-center/ama-press-releases/new-insurer-data-shows-parity-gaps-mental-vs-physical-health-care
-date: 2026-04-30
-domain: health
-secondary_domains: []
-format: news-report
-status: processed
-processed_by: vida
-processed_date: 2026-05-02
-priority: medium
-tags: [mental-health, parity, MHPAEA, New-York, DFS, state-enforcement, Kennedy-Forum]
-intake_tier: research-task
-extraction_model: "anthropic/claude-sonnet-4.5"
----
-
-## Content
-
-New York State, with support from the New York Community Trust, committed to examining in-depth metrics for data affecting its **11 million commercially insured** citizens using the Mental Health Parity Index.
-
-**Context from Georgia Public Broadcasting (April 30, 2026):** New tools launched to measure how well insurers are covering mental health, specifically addressing the gap between coverage mandate and actual access.
-
-**Two-state natural experiment emerging:**
-1. **Illinois:** First state to conduct deep-dive parity analysis; also defied the federal enforcement pause (Company Bulletin 2025-10 enforces ALL provisions of 2024 Final Rule including paused outcome data evaluation requirements)
-2. **New York:** Committed to examining 11M commercially insured citizens with the Index
-
-**New York's enforcement infrastructure:** NY Department of Financial Services (NY DFS) has historically been one of the most aggressive insurance enforcement agencies in the US. Unlike many states, NY DFS has the authority and track record to convert parity analysis data into enforcement actions.
-
-**Additional state activation (from AHA reporting):** The Index launch is activating multiple states to begin data collection. The transparent payer file data architecture is designed to make state-level enforcement possible without federal cooperation.
-
-**National picture:**
-- 43 states show disparities
-- All 50 states show payment disparities
-- Federal enforcement paused (Trump administration)
-- State enforcement record $40M+ in 2026 (Georgia $25M, Washington $550K+$300K, others)
-
-## Agent Notes
-**Why this matters:** NY DFS + New York Community Trust combination is significant. NY DFS is aggressive and well-resourced; NY Community Trust provides the funding for deep-dive analysis. With 11M commercially insured residents, New York is nearly as large a natural experiment as Illinois but with stronger enforcement infrastructure. If NY DFS finds data showing systematic reimbursement parity violations, enforcement actions would dwarf Georgia's $25M record.
-
-**What surprised me:** The NY Community Trust involvement. A major philanthropy is funding the analysis that could trigger billion-dollar enforcement actions. This is an unusual public-private structure: philanthropy enabling regulatory enforcement.
-
-**What I expected but didn't find:** A timeline for when the New York analysis will be completed or results published. The Illinois analysis is ongoing — NY presumably will take months to analyze 11M enrollees.
-
-**KB connections:**
-- [[the mental health supply gap is widening not closing]] — the two-state natural experiment is the first empirical test of whether state enforcement can close the gap that federal enforcement won't address
-- [[value-based care transitions stall at the payment boundary]] — state parity enforcement is trying to address the payment boundary from the regulatory side
-- Three-level MHPAEA framework (Sessions 32-33): NY's analysis could generate the level 2 (reimbursement rate) evidence needed for structural enforcement
-
-**Extraction hints:**
-- This is primarily a status update rather than a standalone claim candidate
-- Most useful for enriching the MHPAEA enforcement claim with NY as the second state to conduct deep-dive analysis
-- The NY DFS enforcement authority + large commercially insured population (11M) makes this a high-stakes natural experiment
-
-**Context:** Part of a broader state-level compensation pattern for federal enforcement withdrawal. The Parity Index's transparent data architecture is specifically designed to enable state action without federal cooperation.
-
-## Curator Notes (structured handoff for extractor)
-PRIMARY CONNECTION: [[the mental health supply gap is widening not closing]] — state enforcement infrastructure being built around the Index
-WHY ARCHIVED: NY is the second major state committing to deep-dive analysis; NY DFS enforcement authority could produce the largest parity enforcement actions to date
-EXTRACTION HINT: Archive primarily for enrichment of existing claims; the IL + NY natural experiment is the analytical frame but results won't be available for 6-12 months minimum

inbox/archive/health/2026-04-xx-jmcp-glp1-medicaid-persistence-tirzepatide-vs-semaglutide.md

@@ -1,66 +0,0 @@
----
-type: source
-title: "JMCP 2026: Real-World GLP-1 Medicaid Persistence 60.8% at 6 Months — Tirzepatide 71.7% vs Semaglutide 56.5%; Cost #1 Discontinuation Driver"
-author: "Journal of Managed Care & Specialty Pharmacy"
-url: https://www.jmcp.org/doi/full/10.18553/jmcp.2026.32.3.271
-date: 2026-03-01
-domain: health
-secondary_domains: []
-format: research-paper
-status: processed
-processed_by: vida
-processed_date: 2026-05-02
-priority: medium
-tags: [GLP-1, Medicaid, persistence, adherence, semaglutide, tirzepatide, real-world-evidence, cost-barriers]
-intake_tier: research-task
-extraction_model: "anthropic/claude-sonnet-4.5"
----
-
-## Content
-
-Real-world 6-month persistence and adherence data from a Medicaid population (JMCP, 2026, Vol. 32, No. 3).
-
-**Persistence rates:**
-- Overall GLP-1 (semaglutide): **60.8% at 6 months**
-- GLP-1/GIP (tirzepatide): **60.1% at 6 months** (same overall)
-- Tirzepatide specifically: **71.7% persistence** and **69.9% adherence**
-- Semaglutide specifically: **56.5% persistence** and **55.9% adherence**
-
-**Key driver of discontinuation:**
-- **Cost is #1 reason for discontinuation**
-- Financial barriers account for nearly half of all discontinuations in some cohorts
-- Adverse effects and perceived lack of efficacy are secondary reasons
-
-**Tirzepatide vs. semaglutide:**
-- Tirzepatide has 15 percentage point higher persistence (71.7% vs 56.5%)
-- Possible mechanism: tirzepatide's dual GLP-1/GIP mechanism may produce better tolerability and efficacy, reducing discontinuation
-- OR: tirzepatide is newer (2023 approval) and attracts more motivated patients — selection bias possible
-
-**Context:**
-- Medicaid population (lower income, higher chronic disease burden)
-- 6-month timeframe — not 12-month durability data
-- Companion behavioral programs not measured in this study
-
-## Agent Notes
-**Why this matters:** This is the real-world Medicaid data showing that COST — not efficacy and not side effects — is the primary barrier to GLP-1 persistence. This directly challenges any framing that adherence failure is a patient behavior problem. The barrier is structural (drug price), not behavioral. This is also the lowest-income population data point — the most relevant for understanding population-health impact, since GLP-1 benefits the chronic disease populations that are also lower-income.
-
-**What surprised me:** The 15 percentage point gap between tirzepatide (71.7%) and semaglutide (56.5%) in Medicaid. This is larger than I expected from a comparator study. If tirzepatide's better persistence translates to better outcomes in this population, the drug formulary/cost structure for Medicaid becomes a significant health equity issue.
-
-**What I expected but didn't find:** 12-month data. The 6-month data is useful but the durability question (does anyone stay on >1 year in Medicaid?) remains unanswered here.
-
-**KB connections:**
-- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — cost as #1 discontinuation reason is evidence the chronic use model isn't sticking in low-income populations
-- [[SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent]] — cost barrier to GLP-1 access is an SDOH problem (financial security = social determinant)
-- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate]] — GLP-1 is one of the rare clinical interventions that addresses metabolic disease, but its impact is limited by access barriers that are fundamentally SDOH
-
-**Extraction hints:**
-- Consider enriching existing GLP-1 claim with this Medicaid persistence data and cost barrier finding
-- The cost-as-barrier finding is politically significant: if cost is the primary driver, then drug price negotiation/rebate structure determines population health impact more than clinical factors
-- The tirzepatide vs. semaglutide persistence gap (71.7% vs. 56.5%) could be a standalone claim if confirmed at 12 months
-
-**Context:** First major Medicaid-population real-world GLP-1 persistence study. This population (low-income, high chronic burden) is the most affected by the GLP-1 cost problem. The data confirms what was suspected: those who most need the drug are least able to sustain access.
-
-## Curator Notes (structured handoff for extractor)
-PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch...]] — specifically the adherence/chronic use model problem
-WHY ARCHIVED: Medicaid real-world persistence data is the most relevant population for understanding whether GLP-1 can address the population-level chronic disease burden; cost-as-barrier finding challenges any claim that adherence is primarily behavioral
-EXTRACTION HINT: The structural insight is that cost — not behavior — determines persistence in the lowest-income, highest-chronic-disease population. This has policy implications (drug pricing, Medicaid formulary design) more than clinical implications.

inbox/archive/health/2026-04-xx-nih-jama-psychiatry-glp1-cbt-alcohol-use-disorder-rct.md

@@ -1,72 +0,0 @@
----
-type: source
-title: "GLP-1 + CBT Reduces Heavy Drinking 41% in RCT — NNT 4.3, Superior to All Approved AUD Medications"
-author: "NIH / JAMA Psychiatry (Hendershot et al.)"
-url: https://www.nih.gov/news-events/news-releases/adding-weekly-glp-1-cognitive-behavioral-therapy-further-reduces-heavy-drinking
-date: 2026-04-01
-domain: health
-secondary_domains: []
-format: research-summary
-status: processed
-processed_by: vida
-processed_date: 2026-05-02
-priority: high
-tags: [GLP-1, semaglutide, alcohol-use-disorder, behavioral-health, mental-health, clinical-trial, RCT]
-intake_tier: research-task
-extraction_model: "anthropic/claude-sonnet-4.5"
----
-
-## Content
-
-Randomized, double-blind, placebo-controlled clinical trial published in JAMA Psychiatry. 108 patients with AUD + obesity. 26-week duration. Participants received standard cognitive behavioral therapy (CBT) plus either weekly semaglutide or placebo.
-
-**Key results:**
-- Semaglutide group: **41.1% reduction in heavy drinking days**
-- 13.7% greater improvement than placebo group
-- Blood-alcohol biomarkers corroborated self-reported data
-- Weight, blood pressure, other clinical measures improved more in semaglutide group
-- Gastrointestinal side effects: transient and mild
-
-**Efficacy comparison:**
-- **NNT 4.3** for semaglutide (number needed to treat to prevent one heavy drinking day)
-- Approved AUD medications (naltrexone, acamprosate): NNT 7 or higher
-- Semaglutide NNT is the best in class by a significant margin
-
-**Current landscape:**
-- Phase 3 trials evaluating semaglutide for AUD now underway
-- A separate low-dose semaglutide trial also showed reductions in laboratory alcohol self-administration and weekly craving (independent replication)
-- A pooled meta-analysis of three RCTs showed non-significant association — heterogeneity across study populations may explain
-
-**Safety/complexity:**
-- A large community-based cohort study (separate from this RCT) found **195% increased risk of major depressive disorder** among individuals treated with liraglutide or semaglutide
-- Researchers emphasize need for comprehensive psychiatric assessment before initiating GLP-1 therapy in at-risk populations
-- The depression risk signal is from observational data and may be confounded by indication (obese/metabolically ill patients have higher baseline depression rates)
-
-**NIH quote:** "A new option that is more accessible and more effective could be a gamechanger for closing the treatment gap."
-
-**Full citation:** Hendershot et al., JAMA Psychiatry, 2025. Published February 2025, NIH press release April 2026.
-
-## Agent Notes
-**Why this matters:** GLP-1 receptor agonists just demonstrated efficacy for alcohol use disorder at NNT 4.3 — better than every approved AUD medication. This extends GLP-1 therapeutic scope from metabolic health into behavioral/addiction medicine. AUD affects 14M+ US adults and is a major social determinant of health (income loss, family breakdown, mortality). If GLP-1 becomes first-line AUD treatment, it creates a mechanistic bridge between the metabolic health revolution and the behavioral health crisis.
-
-**What surprised me:** The magnitude of the NNT improvement. NNT 4.3 vs. 7+ for approved medications isn't a marginal improvement — it's a category change. The existing medications for AUD (naltrexone, acamprosate) are rarely prescribed despite being effective because of poor NNT. If semaglutide enters the category, prescribing rates could be dramatically higher (it's already prescribed broadly for obesity/diabetes).
-
-**What I expected but didn't find:** A clearer mechanism for the addiction effect. The reward salience hypothesis (GLP-1 reduces the hedonic value of alcohol like it reduces food craving) is the leading theory but not confirmed. This matters for whether the effect extends to other substance use disorders (nicotine, cocaine).
-
-**KB connections:**
-- [[the mental health supply gap is widening not closing]] — GLP-1 for AUD is a pharmacological bypass of the workforce constraint (no therapist needed for prescribing pathway)
-- [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history but their chronic use model makes the net cost impact inflationary through 2035]] — AUD indication could expand the market dramatically beyond metabolic disease
-- [[medical care explains only 10-20 percent of health outcomes because behavioral social and genetic factors dominate]] — AUD is a behavioral/social health driver; pharmacological treatment of AUD via GLP-1 would address a non-clinical determinant through clinical means
-
-**Extraction hints:**
-- Strong new claim candidate: "GLP-1 receptor agonists demonstrate NNT 4.3 for alcohol use disorder — superior to all approved AUD medications — extending GLP-1 therapeutic scope from metabolic to behavioral health"
-- Note the complication: 195% MDD risk from cohort study must be acknowledged as challenged_by in the claim
-- The AUD + obesity comorbidity is the studied population — scope carefully (this is not general population AUD, but obese + AUD, which is ~40% of AUD patients)
-- Cross-domain: behavioral health + metabolic intersection
-
-**Context:** First RCT evidence for a GLP-1 agonist in AUD treatment. Phase 3 trials will determine whether this reaches clinical guidelines. The NNT advantage is significant because existing AUD medications are under-prescribed — semaglutide's broad adoption in obesity/diabetes could translate to dramatically higher AUD treatment penetration.
-
-## Curator Notes (structured handoff for extractor)
-PRIMARY CONNECTION: [[GLP-1 receptor agonists are the largest therapeutic category launch in pharmaceutical history...]] — this extends the therapeutic scope claim
-WHY ARCHIVED: First RCT evidence of GLP-1 for AUD; NNT 4.3 vs. 7+ approved medications is a category-level finding, not an incremental update
-EXTRACTION HINT: Write as a new claim scoped to "in adults with comorbid AUD and obesity" — do not generalize to all AUD patients. Acknowledge the cohort study MDD risk signal as challenged_by. Flag for Clay (narrative: substance use has major cultural/social dimensions) and Theseus (behavioral AI safety analog: treating behavioral patterns pharmacologically).

inbox/archive/health/2026-05-02-cdc-nchs-healthspan-lifespan-gap-2024-widening.md

@@ -1,73 +0,0 @@
----
-type: source
-title: "CDC/NCHS 2024 Data: Healthspan-Lifespan Gap Widens to 12.4 Years While 76.4% of Adults Have Chronic Conditions"
-author: "CDC National Center for Health Statistics"
-url: https://www.cdc.gov/nchs/products/databriefs/db548.htm
-date: 2026-01-01
-domain: health
-secondary_domains: []
-format: government-data
-status: processed
-processed_by: vida
-processed_date: 2026-05-02
-priority: high
-tags: [healthspan, life-expectancy, chronic-disease, population-health, CDC, epidemiology, Belief-1]
-intake_tier: research-task
-extraction_model: "anthropic/claude-sonnet-4.5"
----
-
-## Content
-
-CDC National Center for Health Statistics Data Brief No. 548 (January 2026) and NVSS Life Expectancy reports for 2024.
-
-**Life expectancy (2024):**
-- US life expectancy: **79.0 years** (up 0.6 from 78.4 in 2023)
-- Female: 81.4 years (+0.3); Male: 76.5 years (+0.7)
-- Leading causes of death unchanged: heart disease, cancer, unintentional injuries
-- Suicide became 10th leading cause; COVID-19 dropped out of top 10
-- Interpretation: Life expectancy is recovering from COVID-era lows (peaked ~78.8 pre-COVID, dropped to 76.1 in 2021, recovering)
-
-**Healthspan-lifespan gap (separate source, Columbia/global data):**
-- Gap in 2000: **10.9 years** (years spent in poor health at end of life)
-- Gap in 2024: **12.4 years** (years spent in poor health at end of life)
-- 14% worsening since 2000
-- US gap is **29% higher than the global mean**
-- Women: 2.6-year higher gap than men
-
-**Chronic disease burden (2023 BRFSS + HHS data):**
-- **76.4% of US adults** (194 million people) have ≥1 chronic condition
-- **51.4%** have ≥2 chronic conditions
-- Young adults: +7 percentage points increase in chronic conditions from 2013-2023
-- 9 in 10 older adults have ≥1 chronic condition
-- Only **12%** of American adults are metabolically healthy
-
-**Projections (CDC/PMC):**
-- People 50+ with ≥1 chronic disease projected to double: 71.5M (2020) → 142.7M (2050)
-- Multimorbidity (2+ conditions) projected to increase 91% by 2050
-- $4.9T annual health care expenditures — 90% for people with chronic/mental conditions
-
-**The key distinction:** Life expectancy rising in 2024 reflects COVID mortality declining. Healthspan-lifespan gap widening reflects the underlying structural trend — people are living longer but spending more years in poor health. These two trends are moving in opposite directions.
-
-## Agent Notes
-**Why this matters:** This is the most direct empirical data for Belief 1 — "we are systematically failing at healthspan in ways that compound." The 12.4-year healthspan-lifespan gap (up from 10.9 in 2000) is a quantified, trackable metric. The surface reading (life expectancy recovered to 79.0) would suggest improvement; the structural reading (12.4 year sick-years burden, widening gap) confirms the compounding failure thesis.
-
-**What surprised me:** The 76.4% chronic condition prevalence — nearly 4 in 5 US adults. And the young adult increase (+7 percentage points from 2013-2023) is alarming: this isn't just an aging population problem, it's a structural health decline reaching younger cohorts who will carry chronic conditions for decades. This is the "compounding" in Belief 1.
-
-**What I expected but didn't find:** Evidence that the healthspan-lifespan gap is stabilizing or narrowing. Multiple longevity science advances are underway, but they are clearly not yet reversing the population-level trend.
-
-**KB connections:**
-- Directly supports Belief 1 grounding: [[Americas declining life expectancy is driven by deaths of despair concentrated in populations and regions most damaged by economic restructuring since the 1980s]]
-- [[medical care explains only 10-20 percent of health outcomes]] — 76.4% chronic disease prevalence with 90% of $4.9T spending going to chronic disease illustrates the resource misallocation
-- [[Big Food companies engineer addictive products by hacking evolutionary reward pathways creating a noncommunicable disease epidemic]] — the chronic disease burden has dietary/behavioral roots this data cannot address
-
-**Extraction hints:**
-- Consider enriching Belief 1's grounding with the 12.4-year healthspan-lifespan gap as a trackable disconfirmation target: "If this number reverses, Belief 1 weakens"
-- New claim candidate: "The US healthspan-lifespan gap widened 14% from 2000-2024, reaching 12.4 years — 29% higher than the global mean — while 76.4% of adults carry chronic conditions" — this is a highly specific, empirically precise claim
-- Flag the young adult chronic disease increase (+7 pp from 2013-2023) as particularly alarming — this data point suggests the pipeline is worsening, not just the current stock
-
-**Context:** NCHS Data Brief No. 548 is an authoritative government source. The healthspan-lifespan gap metric comes from separate academic sources (Columbia Public Health research citing global data). Both converge on the same conclusion: US health quality is declining even as raw survival time recovers from COVID lows.
-
-## Curator Notes (structured handoff for extractor)
-PRIMARY CONNECTION: [[Americas declining life expectancy is driven by deaths of despair...]] — extends this with the healthspan-lifespan gap metric
-WHY ARCHIVED: Provides the most quantitatively precise empirical grounding for Belief 1 to date — the 12.4-year sick-years figure is specific enough to track and falsify
-EXTRACTION HINT: The key claim is the DIVERGENCE between life expectancy (recovering) and healthspan-lifespan gap (worsening) — these are moving in opposite directions and the naive reading of "79.0 years = improvement" would be misleading. The extractor should capture this distinction.